Categories AlphaGraphs, Earnings, Health Care

Regeneron beats market estimates on Q3 revenue and profits

Regeneron Pharmaceuticals Inc. (REGN) surpassed market expectations on revenue and earnings for the third quarter of 2018. The stock was up over 1% in early trading hours on Tuesday.

Total revenues grew 11% to $1.66 billion versus the prior-year quarter. The company also saw increases in revenues from its Sanofi and Bayer collaborations, which were driven by higher net sales of Dupixent and Praluent as well as higher international sales of EYLEA. Net product sales grew to $1.02 billion from $957 million last year, helped by higher EYLEA net product sales.

Regeneron third quarter 2018 Earnings Infographic
Regeneron Q3 2018 Earnings Infographic

On a GAAP basis, net income increased more than 50% to $595 million or $5.17 per share versus the year-ago quarter. Adjusted net income grew more than 40% to $675 million or $5.87 per share from last year.

Leonard S. Schleifer, President and CEO, said, “Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results. In addition to EYLEA reaching over $1 billion in quarterly US net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy. Dupixent is now approved in the US for both atopic dermatitis and asthma and under regulatory review for the treatment of adolescents with atopic dermatitis – with another submission planned in chronic rhinosinusitis with nasal polyps. We also recently reported positive Phase 3 results for EYLEA in diabetic retinopathy, and expect an FDA action on our supplemental application for this indication in the first half of 2019.”

Eylea lifts Regeneron Q2 earnings

During the third quarter, Regeneron entered into a collaboration agreement with bluebird bio, Inc. for the research, development, and commercialization of novel immune cell therapies for cancer.

The company updated its guidance for the full year of 2018 and now expects Sanofi collaboration revenue to come in the range of $430 million to $455 million versus the previous guidance of $455 million to $485 million.


Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment

Viewing Highlight